Login to Your Account



Search

Search results

Pharma: Clinic roundup

Pfizer Inc. , of New York, reported results from two phase II studies of bivalent rLP2086, its recombinant vaccine candidate in development for the prevention of invasive meningococcal disease caused by Neisseria meningitides serogroup B in subje ...

BioWorld Today - Staff - 2014-05-12 00:00 - 0 comments - 0 attachments

Clinic roundup

Aicuris AG , of Wuppertal, Germany, and Merck & Co. Inc. , of Whitehouse Station, N.J., said phase II results were published in the New England Journal of Medicine showing the safety and efficacy of letermovir, an oral antiviral agent for ...

BioWorld Today - Staff - 2014-05-09 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Dompe Group , of Milan, reported preliminary phase I results confirming the tolerability of its recombinant human nerve growth factor (rhNGF), in development for ophthalmic use as a treatment for neurotrophic keratitis. (BioWorld-Today-2014- ...

BioWorld Today - Staff - 2014-05-09 00:00 - 0 comments - 0 attachments

Clinic roundup

Epizyme Inc. , of Cambridge, Mass., said it started a phase Ib open-label study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene (MLL-r). (BioWorld-Today-2014-05-08) ...

BioWorld Today - Staff - 2014-05-08 00:00 - 0 comments - 0 attachments

Clinic roundup

Rhythm Pharmaceuticals Inc. , of Boston, presented phase II results at the Digestive Disease Week conference in Chicago showing that relamorelin, administered twice daily for four weeks in patients with moderate to severe gastroparesis, significant ...

BioWorld Today - Staff - 2014-05-07 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Novartis AG , of Basel, Switzerland, presented results at the European Congress of Endocrinology in Wroclaw, Poland, from a pivotal phase III study of Signifor LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of c ...

BioWorld Today - Staff - 2014-05-07 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

UCB SA , of Brussels, Belgium, reported results from the PRECiSE 3 seven-year open-label extension trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease. (Bi ...

BioWorld Today - Staff - 2014-05-06 00:00 - 0 comments - 0 attachments

Clinic roundup

Advaxis Inc. , of Princeton, N.J, said it plans to start a clinical development program with ADXS-cHER2, an immunotherapy candidate designed to target the HER2 oncogene, for the treatment of pediatric osteosarcoma. (BioWorld-Today-2014-0 ...

BioWorld Today - Staff - 2014-05-06 00:00 - 0 comments - 0 attachments

Clinic roundup

Ruthigen Inc. , of Santa Rosa, Calif., said it submitted an investigational new drug application for lead candidate RUT58-60, a broad-spectrum anti-infective drug for prophylactic use during invasive medical procedures. (BioWorld-Today-2014- ...

BioWorld Today - Staff - 2014-05-05 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

CSL Behring Ltd. , of King of Prussia, Pa., said the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the efficacy, safety and pharmacokinetics of its investigational recombinant factor VIII single chain (rVIII-Sin ...

BioWorld Today - Staff - 2014-05-05 00:00 - 0 comments - 0 attachments